RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting m(6)A methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype.

RBM15 通过靶向 TNFSF9 的 m(6)A 甲基化并诱导肿瘤相关巨噬细胞极化为 M2 表型，增强三阴性乳腺癌的紫杉醇耐药性